FPR1 and neoplasm: One of the first studies aimed to assess the effects of pharmacological treatments for cancer therapy by using an on chip approach is represented by a study addressing the role of formyl peptide receptor 1 (FPR1)/annexin a1 (Anxa1) axis in anti-tumor response to anthracycline-based chemotherapy (Vacchelli et al., 2015).